169 related articles for article (PubMed ID: 3191936)
1. Phenotyping polymorphic drug metabolism in the French Caucasian population.
Jacqz E; Dulac H; Mathieu H
Eur J Clin Pharmacol; 1988; 35(2):167-71. PubMed ID: 3191936
[TBL] [Abstract][Full Text] [Related]
2. Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism.
Guttendorf RJ; Britto M; Blouin RA; Foster TS; John W; Pittman KA; Wedlund PJ
Br J Clin Pharmacol; 1990 Apr; 29(4):373-80. PubMed ID: 2328190
[TBL] [Abstract][Full Text] [Related]
3. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.
Wedlund PJ; Aslanian WS; McAllister CB; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1984 Dec; 36(6):773-80. PubMed ID: 6499356
[TBL] [Abstract][Full Text] [Related]
4. Polymorphism of dextromethorphan oxidation in a French population.
Larrey D; Amouyal G; Tinel M; Letteron P; Berson A; Labbe G; Pessayre D
Br J Clin Pharmacol; 1987 Nov; 24(5):676-9. PubMed ID: 3435696
[TBL] [Abstract][Full Text] [Related]
5. GC and GC-MS procedures for simultaneous phenotyping with dextromethorphan and mephenytoin.
Baumann P; Jonzier-Perey M
Clin Chim Acta; 1988 Feb; 171(2-3):211-22. PubMed ID: 3370821
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of dextromethorphan O-demethylation in man.
Küpfer A; Schmid B; Pfaff G
Xenobiotica; 1986 May; 16(5):421-33. PubMed ID: 3739367
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.
Küpfer A; Preisig R
Eur J Clin Pharmacol; 1984; 26(6):753-9. PubMed ID: 6489416
[TBL] [Abstract][Full Text] [Related]
8. Polymorphic debrisoquine and mephenytoin hydroxylation in patients with pulmonary hypertension of vascular origin after aminorex fumarate.
Saner H; Gurtner HP; Preisig R; Küpfer A
Eur J Clin Pharmacol; 1986; 31(4):437-42. PubMed ID: 3816924
[TBL] [Abstract][Full Text] [Related]
9. Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians.
Inaba T; Jurima M; Nakano M; Kalow W
Clin Pharmacol Ther; 1984 Nov; 36(5):670-6. PubMed ID: 6488688
[TBL] [Abstract][Full Text] [Related]
10. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics.
Sohn DR; Kusaka M; Ishizaki T; Shin SG; Jang IJ; Shin JG; Chiba K
Clin Pharmacol Ther; 1992 Aug; 52(2):160-9. PubMed ID: 1505151
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians.
Jurima M; Inaba T; Kadar D; Kalow W
Br J Clin Pharmacol; 1985 Apr; 19(4):483-7. PubMed ID: 3994895
[TBL] [Abstract][Full Text] [Related]
12. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.
Nakamura K; Goto F; Ray WA; McAllister CB; Jacqz E; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1985 Oct; 38(4):402-8. PubMed ID: 4042523
[TBL] [Abstract][Full Text] [Related]
13. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
[TBL] [Abstract][Full Text] [Related]
14. Polymorphism of debrisoquine and mephenytoin hydroxylation among Estonians.
Kiivet RA; Svensson JO; Bertilsson L; Sjöqvist F
Pharmacol Toxicol; 1993 Feb; 72(2):113-5. PubMed ID: 8474964
[TBL] [Abstract][Full Text] [Related]
15. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.
Tamminga WJ; Wemer J; Oosterhuis B; Weiling J; Wilffert B; de Leij LF; de Zeeuw RA; Jonkman JH
Eur J Clin Pharmacol; 1999 May; 55(3):177-84. PubMed ID: 10379632
[TBL] [Abstract][Full Text] [Related]
16. Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo.
Meier UT; Dayer P; Malè PJ; Kronbach T; Meyer UA
Clin Pharmacol Ther; 1985 Nov; 38(5):488-94. PubMed ID: 4053486
[TBL] [Abstract][Full Text] [Related]
17. Genetically determined oxidation polymorphism and drug hepatotoxicity. Study of 51 patients.
Larrey D; Tinel M; Amouyal G; Freneaux E; Berson A; Fouin-Fortunet H; Babany G; Letteron P; Iglicki F; Slama JL
J Hepatol; 1989 Mar; 8(2):158-64. PubMed ID: 2715619
[TBL] [Abstract][Full Text] [Related]
18. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation.
Schmid B; Bircher J; Preisig R; Küpfer A
Clin Pharmacol Ther; 1985 Dec; 38(6):618-24. PubMed ID: 4064464
[TBL] [Abstract][Full Text] [Related]
19. Determination of dextromethorphan metabolizer phenotype in healthy volunteers.
Hildebrand M; Seifert W; Reichenberger A
Eur J Clin Pharmacol; 1989; 36(3):315-8. PubMed ID: 2744072
[TBL] [Abstract][Full Text] [Related]
20. The mephenytoin (cytochrome P450 2C 19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos.
Evans DA; Krahn P; Narayanan N
Pharmacogenetics; 1995 Apr; 5(2):64-71. PubMed ID: 7663530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
